Skip to content Skip to footer
Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Shots: Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnership To tackle such scenarios, companies are cautious enough to make backup plans beforehand…

Read more

Viewpoints_Dr. Bill La Via

Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Respiratory Syncytial Virus (RSV)

Shots: Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' health Bill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID) The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…

Read more